- Home
- FRME vs CDTX Comparison
FRME vs CDTX Comparison
Compare FRME & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRME
- CDTX
- Stock Information
- Founded
- FRME 1893
- CDTX 2012
- Country
- FRME United States
- CDTX United States
- Employees
- FRME N/A
- CDTX N/A
- Industry
- FRME Major Banks
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FRME Finance
- CDTX Health Care
- Exchange
- FRME Nasdaq
- CDTX Nasdaq
- Market Cap
- FRME 2.3B
- CDTX 2.8B
- IPO Year
- FRME N/A
- CDTX 2015
- Fundamental
- Price
- FRME $37.19
- CDTX $219.72
- Analyst Decision
- FRME Buy
- CDTX Buy
- Analyst Count
- FRME 4
- CDTX 13
- Target Price
- FRME $47.33
- CDTX $119.44
- AVG Volume (30 Days)
- FRME 220.1K
- CDTX 2.2M
- Earning Date
- FRME 10-22-2025
- CDTX 11-06-2025
- Dividend Yield
- FRME 3.87%
- CDTX N/A
- EPS Growth
- FRME 32.99
- CDTX N/A
- EPS
- FRME 4.00
- CDTX N/A
- Revenue
- FRME $649,589,000.00
- CDTX N/A
- Revenue This Year
- FRME $13.84
- CDTX N/A
- Revenue Next Year
- FRME $14.34
- CDTX N/A
- P/E Ratio
- FRME $9.30
- CDTX N/A
- Revenue Growth
- FRME 9.53
- CDTX N/A
- 52 Week Low
- FRME $33.13
- CDTX $15.22
- 52 Week High
- FRME $45.62
- CDTX $220.46
- Technical
- Relative Strength Index (RSI)
- FRME 56.85
- CDTX 88.61
- Support Level
- FRME $35.03
- CDTX $218.86
- Resistance Level
- FRME $37.47
- CDTX $220.46
- Average True Range (ATR)
- FRME 0.90
- CDTX 3.01
- MACD
- FRME 0.25
- CDTX 6.76
- Stochastic Oscillator
- FRME 89.84
- CDTX 99.39
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.